No Data
No Data
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
Options Market Statistics: Palantir Shares See Volatility Ahead of Earnings; Options Pop
Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress
Larimar Therapeutics | 10-Q: Q1 2025 Earnings Report
Larimar Therapeutics Options Spot-On: On April 30th, 51,651 Contracts Were Traded, With 7,659 Open Interest
Express News | Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate
74952387 : nice
skumaar42 : Great info!
74128907 :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)